The science
Ipamorelin research, mechanism first and evidence-tiered
What was measured, in which species, at what dose — with ipamorelin's own data kept separate from the broader peptide-class evidence.
Start here
Ipamorelin research divides into two tiers, and keeping them apart is the whole point of an honest digest. The first tier is studies of ipamorelin itself: a founding pharmacology paper, a human pharmacokinetic study, one failed human trial, and a handful of rodent experiments on bone and weight. The second tier is class-level evidence — work done with ipamorelin's chemical relatives (GHRP-6, GHRP-2, hexarelin, CJC-1295) that explains how the family behaves but does not, on its own, prove anything about ipamorelin specifically. This page walks the mechanism first, in plain terms — how a five-amino-acid peptide flips a receptor switch to release growth hormone — then lays the studies out tier by tier. Where a claim leans on a relative rather than on ipamorelin, the text says so. Jargon is unpacked the first time it appears.
What is ipamorelin peptide, structurally
Ipamorelin peptide is a synthetic pentapeptide — five amino acids in a chain — with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 [1]. Two of those building blocks are mirror-image (D-form) amino acids and one is a non-natural unit (Aib, alpha-aminoisobutyric acid) sitting at the front of the chain; together they make the molecule harder for the body's enzymes to chew up [1]. It was derived from an earlier peptide, GHRP-1, by removing a central two-amino-acid segment. Its molecular weight is about 712 daltons. Chemically, then, it is a deliberately engineered, protease-resistant ghrelin mimic — built to do one job, release growth hormone, with as little off-target noise as possible [1].
What does ipamorelin peptide do at the receptor
What ipamorelin peptide does, in mechanism, is bind and activate the GHS-R1a — the growth-hormone secretagogue receptor type 1a, better known as the ghrelin receptor — on pituitary somatotrophs (the growth-hormone-making cells) [1]. Activation runs through a Gq/phospholipase-C cascade that raises intracellular calcium and triggers a discrete pulse of growth-hormone release [1]. The defining result from the 1998 characterization: potent growth-hormone release comparable to GHRP-6, but with no meaningful rise in ACTH or cortisol even more than two-hundred-fold above the growth-hormone ED50 — the selectivity that names the compound [1]. Downstream, growth hormone can raise hepatic IGF-1, but notably the short rat bone study saw skeletal growth without a measurable systemic IGF-1 change, hinting at a partly local, pulse-driven effect [4].
The human evidence: pharmacokinetics and one failed trial
Two human datasets anchor everything. The first, a 1999 population pharmacokinetic-pharmacodynamic study in healthy men (n=8 per dose, five intravenous infusions from 4.21 to 140.45 nmol/kg), found dose-proportional kinetics, a terminal half-life of roughly two hours, clearance of 0.078 L/h/kg, and a single growth-hormone pulse peaking near forty minutes [2]. The second is the decisive one: a 2014 Phase 2 randomized controlled trial (NCT00672074) gave 114 bowel-resection patients 0.03 mg/kg intravenously twice daily for up to seven days to speed bowel recovery. It missed its primary endpoint — first tolerated meal at 25.3 hours versus 32.6 hours on placebo (p=0.15) — though it raised no ipamorelin-specific safety alarm in that short window (treatment-emergent adverse events 87.5 percent versus 94.8 percent on placebo) [3]. That is the entire controlled human efficacy record, and it is negative.
Rodent and animal findings: bone and weight
Animal work is where ipamorelin's positive signals live. In adult female Sprague-Dawley rats, subcutaneous ipamorelin at 18, 90 and 450 micrograms per day (split three times daily for fifteen days) raised the long-bone growth rate from 42 to 44, 50 and 52 micrometres per day, dose-dependently, with no change in total IGF-1 or bone-turnover markers [4]. In the most recent published in-vivo study, a 2024 ferret cachexia model, intraperitoneal ipamorelin at 1 to 3 mg/kg cut cisplatin-driven weight loss by about 24 percent in the delayed phase, though it produced no anti-emetic effect [5]. Both are clean, cited animal findings. Neither has a human counterpart, and the leap from a ferret's body weight to a person's body composition is exactly the leap the marketing makes and the evidence does not.
Class-level combination evidence: real, but not about ipamorelin alone
The synergy that justifies stacking is demonstrated across the peptide family, not in ipamorelin head-to-head trials. In rats neutralized of their own growth-hormone-releasing hormone, exogenous GHRH plus a GHRP produced growth-hormone peaks greater than the sum of each alone [8], and blocking endogenous GHRH attenuated GHRP-6 activity — proving GHRH tone is required for a secretagogue to work fully [9]. In growth-hormone-releasing-hormone-knockout mice, a GHRH analog plus GHRP-2 produced more growth than the analog alone, while GHRP-2 by itself did nothing [10]. A human study with hexarelin showed a GHRP-plus-GHRH combination kept releasing growth hormone even under high somatostatin (the body's "stop" signal) that blunted GHRH alone [7]. A comprehensive review confirms this is a class-wide property of all GH secretagogues [12]. Every one of these uses a relative of ipamorelin — the principle is sound, the ipamorelin-specific combination trial does not exist.
The somatostatin angle, which the combination exploits
One mechanistic detail explains why the peptide class is so effective in combination, and it is worth stating plainly. The body restrains growth-hormone release with somatostatin, a "stop" signal. Growth-hormone-releasing hormone struggles against high somatostatin tone — but ghrelin and its synthetic mimics both directly stimulate the growth-hormone-making cells and indirectly damp the somatostatin brake, providing two-sided amplification when paired with a GHRH analog [14]. A human study with hexarelin made this concrete: a GHRP-plus-GHRH combination kept producing large growth-hormone responses even under high somatostatin infusion that largely flattened GHRH alone [7]. Comprehensive reviews place this somatostatin-resistance among the class-wide properties of all growth-hormone secretagogues, ipamorelin's structural family included [12]. This is the real pharmacological reason ipamorelin is studied beside a GHRH analog rather than alone — though, again, the demonstrations use relatives, not ipamorelin in a combination trial.
Reading the evidence honestly
Put together, the ipamorelin research tells a coherent and modest story. The mechanism is well characterized and genuinely distinctive — a clean, cortisol-sparing growth-hormone pulse [1]. The human pharmacokinetics are known [2]. The animal efficacy signals on bone [4] and weight preservation [5] are real but species-bound. And the one place the rubber met the road in humans, a controlled efficacy trial, it did not deliver [3]. The combination pharmacology is sound at the class level [9][10], but the specific ipamorelin-plus-GHRH-analog product has never been put to a trial. A reader is well served by holding two ideas at once: ipamorelin is a real, interesting, selective tool with a coherent mechanism, and its human benefit for the purposes it is marketed toward remains unproven. Both statements are true, and a vetted digest refuses to drop either one.
Is ipamorelin FDA approved?
No. Ipamorelin is not FDA approved as a drug for any indication, and it has never been approved by any regulatory authority worldwide. It was investigated — most notably for postoperative ileus, trial NCT00672074 — but that program ended after Phase 2 [3]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-drug-substances list, following the nominator's withdrawal in September 2024, and reviewed it at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting; it is not an approved bulk substance for compounding. It is marketed only as a research chemical, and it is prohibited in sport at all times under the WADA list (category S2), detectable in urine by accredited laboratories.